Report cover image

North America Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model (Cloud-based, On-premises, and Hybrid Model), By Therapeutic Area, By Country and Growth Forecast, 2024 -

Publisher Knowledge Based Value (KBV) Research
Published Dec 13, 2024
Length 160 Pages
SKU # KBV19421911

Description

North America Biosimulation Market Size, Share & Trends Analysis Report By Product, By Pricing Model, By End Use, By Application, By Deployment Model (Cloud-based, On-premises, and Hybrid Model), By Therapeutic Area, By Country and Growth Forecast, 2024 - 2031


The North America Biosimulation Market would witness market growth of 16.1% CAGR during the forecast period (2024-2031).

The US market dominated the North America Biosimulation Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $3,575.5 million by 2031. The Canada market is experiencing a CAGR of 18.7% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 17.7% during (2024 - 2031).

This market is at the forefront of a transformative wave in the healthcare and pharmaceutical industries. This cutting-edge field combines computational science with biology to simulate complex biological systems, offering unprecedented insights into drug development, disease progression, and therapeutic responses.

At its core, they involves creating virtual models of biological systems, enabling scientists to study the intricate processes of the human body without the need for extensive laboratory experiments. This capability has revolutionized pharmaceutical research by allowing researchers to simulate how drugs interact with biological pathways, predict outcomes, and optimize dosing regimens.

Due to growing healthcare expenditures and a changing private healthcare industry, Mexico is becoming a major player in the North American market. The country’s increasing disease burden, such as the projected rise in diabetes cases from 12.8 million in 2019 to 22.3 million by 2045, underscores the critical need for advanced healthcare solutions. These platforms play a vital role in helping healthcare providers optimize drug therapies and manage chronic diseases more effectively. These tools and lifestyle disease management applications are crucial for addressing this growing health crisis. Therefore, with increasing investments in personalized medicine, biologics, and rare disease therapies, North America remains a key driver of growth in the global biosimulation landscape.

Based on Product, the market is segmented into Software (Molecular Modeling & Simulation Software, Clinical Trial Design Software, PK/PD Modeling and Simulation Software, Pbpk Modeling and Simulation Software, Toxicity Prediction Software, and Other Software Type) and Services (Contract Services, Consulting, and Other Services Type). Based on Pricing Model, the market is segmented into License-based Model, Subscription-based Model, Service-based Model, and Pay Per Use Model. Based on End Use, the market is segmented into Life Sciences Companies, Academic Research Institutions, and Other End Use. Based on Application, the market is segmented into Drug Discovery & Development, Disease Modeling, and Other Application. Based on Deployment Model, the market is segmented into Cloud-based, On-premises, and Hybrid Model. Based on Therapeutic Area, the market is segmented into Oncology, Cardiovascular Disease, Infectious Disease, Neurological Disorders, and Other Therapeutic Area. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled
  • Certara, Inc.
  • Dassault Systemes SE
  • Advanced Chemistry Development, Inc.
  • Genedata AG (Danaher Corporation)
  • Instem Group of Companies
  • Chemical Computing Group ULC
  • Simulations Plus, Inc.
  • Schrodinger, Inc.
  • PPD, Inc. (Thermo Fisher Scientific, Inc.)
  • Physiomics Plc
North America Biosimulation Market Report Segmentation

By Product
  • Software
  • Molecular Modeling & Simulation Software
  • Clinical Trial Design Software
  • PK/PD Modeling and Simulation Software
  • Pbpk Modeling and Simulation Software
  • Toxicity Prediction Software
  • Other Software Type
  • Services
  • Contract Services
  • Consulting
  • Other Services Type
By Pricing Model
  • License-based Model
  • Subscription-based Model
  • Service-based Model
  • Pay Per Use Model
By End Use
  • Life Sciences Companies
  • Academic Research Institutions
  • Other End Use
By Application
  • Drug Discovery & Development
  • Disease Modeling
  • Other Application
By Deployment Model
  • Cloud-based
  • On-premises
  • Hybrid Model
By Therapeutic Area
  • Oncology
  • Cardiovascular Disease
  • Infectious Disease
  • Neurological Disorders
  • Other Therapeutic Area
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America

Table of Contents

160 Pages
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Biosimulation Market, by Product
1.4.2 North America Biosimulation Market, by Pricing Model
1.4.3 North America Biosimulation Market, by End Use
1.4.4 North America Biosimulation Market, by Application
1.4.5 North America Biosimulation Market, by Deployment Model
1.4.6 North America Biosimulation Market, by Therapeutic Area
1.4.7 North America Biosimulation Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
Chapter 4. Competition Analysis – Global
4.1 Market Share Analysis, 2023
4.2 Strategies Deployed in Biosimulation Market
4.3 Porter Five Forces Analysis
Chapter 5. North America Biosimulation Market by Product
5.1 North America Software Market by Region
5.2 North America Biosimulation Market by Software Type
5.2.1 North America Molecular Modeling & Simulation Software Market by Country
5.2.2 North America Clinical Trial Design Software Market by Country
5.2.3 North America PK/PD Modeling and Simulation Software Market by Country
5.2.4 North America Pbpk Modeling and Simulation Software Market by Country
5.2.5 North America Toxicity Prediction Software Market by Country
5.2.6 North America Other Software Type Market by Country
5.3 North America Services Market by Region
5.4 North America Biosimulation Market by Services Type
5.4.1 North America Contract Services Market by Country
5.4.2 North America Consulting Market by Country
5.4.3 North America Other Services Type Market by Country
Chapter 6. North America Biosimulation Market by Pricing Model
6.1 North America License-based Model Market by Country
6.2 North America Subscription-based Model Market by Country
6.3 North America Service-based Model Market by Country
6.4 North America Pay Per Use Model Market by Country
Chapter 7. North America Biosimulation Market by End Use
7.1 North America Life Sciences Companies Market by Country
7.2 North America Academic Research Institutions Market by Country
7.3 North America Other End Use Market by Country
Chapter 8. North America Biosimulation Market by Application
8.1 North America Drug Discovery & Development Market by Country
8.2 North America Disease Modeling Market by Country
8.3 North America Other Application Market by Country
Chapter 9. North America Biosimulation Market by Deployment Model
9.1 North America Cloud-based Market by Country
9.2 North America On-premises Market by Country
9.3 North America Hybrid Model Market by Country
Chapter 10. North America Biosimulation Market by Therapeutic Area
10.1 North America Oncology Market by Country
10.2 North America Cardiovascular Disease Market by Country
10.3 North America Infectious Disease Market by Country
10.4 North America Neurological Disorders Market by Country
10.5 North America Other Therapeutic Area Market by Country
Chapter 11. North America Biosimulation Market by Country
11.1 US Biosimulation Market
11.1.1 US Biosimulation Market by Product
11.1.1.1 US Biosimulation Market by Software Type
11.1.1.2 US Biosimulation Market by Services Type
11.1.2 US Biosimulation Market by Pricing Model
11.1.3 US Biosimulation Market by End Use
11.1.4 US Biosimulation Market by Application
11.1.5 US Biosimulation Market by Deployment Model
11.1.6 US Biosimulation Market by Therapeutic Area
11.2 Canada Biosimulation Market
11.2.1 Canada Biosimulation Market by Product
11.2.1.1 Canada Biosimulation Market by Software Type
11.2.1.2 Canada Biosimulation Market by Services Type
11.2.2 Canada Biosimulation Market by Pricing Model
11.2.3 Canada Biosimulation Market by End Use
11.2.4 Canada Biosimulation Market by Application
11.2.5 Canada Biosimulation Market by Deployment Model
11.2.6 Canada Biosimulation Market by Therapeutic Area
11.3 Mexico Biosimulation Market
11.3.1 Mexico Biosimulation Market by Product
11.3.1.1 Mexico Biosimulation Market by Software Type
11.3.1.2 Mexico Biosimulation Market by Services Type
11.3.2 Mexico Biosimulation Market by Pricing Model
11.3.3 Mexico Biosimulation Market by End Use
11.3.4 Mexico Biosimulation Market by Application
11.3.5 Mexico Biosimulation Market by Deployment Model
11.3.6 Mexico Biosimulation Market by Therapeutic Area
11.4 Rest of North America Biosimulation Market
11.4.1 Rest of North America Biosimulation Market by Product
11.4.1.1 Rest of North America Biosimulation Market by Software Type
11.4.1.2 Rest of North America Biosimulation Market by Services Type
11.4.2 Rest of North America Biosimulation Market by Pricing Model
11.4.3 Rest of North America Biosimulation Market by End Use
11.4.4 Rest of North America Biosimulation Market by Application
11.4.5 Rest of North America Biosimulation Market by Deployment Model
11.4.6 Rest of North America Biosimulation Market by Therapeutic Area
Chapter 12. Company Profiles
12.1 Certara, Inc.
12.1.1 Company Overview
12.1.2 Financial Analysis
12.1.3 Regional Analysis
12.1.4 Research & Development Expenses
12.1.5 Recent strategies and developments:
12.1.5.1 Product Launches and Product Expansions:
12.1.5.2 Acquisition and Mergers:
12.1.6 SWOT Analysis
12.2 Dassault Systemes SE
12.2.1 Company Overview
12.2.2 Financial Analysis
12.2.3 Regional Analysis
12.2.4 Research & Development Expense
12.2.5 SWOT Analysis
12.3 Advanced Chemistry Development, Inc.
12.3.1 Company Overview
12.4 Genedata AG (Danaher Corporation)
12.4.1 Company Overview
12.4.2 Financial Analysis
12.4.3 Segmental and Regional Analysis
12.4.4 Research & Development Expense
12.4.5 Recent strategies and developments:
12.4.5.1 Partnerships, Collaborations, and Agreements:
12.5 Instem Group of Companies
12.5.1 Company Overview
12.6 Chemical Computing Group ULC
12.6.1 Company Overview
12.7 Simulations Plus, Inc.
12.7.1 Company Overview
12.7.2 Financial Analysis
12.7.3 Segmental and Regional Analysis
12.7.4 Research & Development Expenses
12.7.5 Recent strategies and developments:
12.7.5.1 Partnerships, Collaborations, and Agreements:
12.7.5.2 Product Launches and Product Expansions:
12.7.5.3 Acquisition and Mergers:
12.7.6 SWOT Analysis
12.8 Schrodinger, Inc.
12.8.1 Company Overview
12.8.2 Financial Analysis
12.8.3 Segmental and Regional Analysis
12.8.4 Research & Development Expenses
12.9 PPD, Inc. (Thermo Fisher Scientific, Inc.)
12.9.1 Company Overview
12.9.2 Financial Analysis
12.9.3 Segmental and Regional Analysis
12.9.4 Research & Development Expenses
12.10. Physiomics Plc
12.10.1 Company Overview
12.10.2 Financial Analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us